Redefining the Prognostic Significance of t(11;14) Multiple Myeloma

被引：2
|
作者：
Bal, Susan
Giri, Smith
Godby, Kelly N.
Costa, Luciano J.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] T(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma
    Garand, R
    Avet-Loiseau, H
    Accard, F
    Moreau, P
    Harousseau, JL
    Bataille, R
    LEUKEMIA, 2003, 17 (10) : 2032 - 2035
  • [32] t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma
    R Garand
    H Avet-Loiseau
    F Accard
    P Moreau
    J L Harousseau
    R Bataille
    Leukemia, 2003, 17 : 2032 - 2035
  • [33] Prognostic significance of detectable rearrangements of T cell receptors γ in patients with multiple myeloma.
    Garicochea, B
    Borioli, RA
    Bendit, I
    Martinez, GA
    BLOOD, 2002, 100 (11) : 374B - 374B
  • [34] Longitudinal Analysis of t(11;14) and t(4;14) Genomes Reveals Distinct Evolutionary Trajectories in Multiple Myeloma
    Hudson-Lund, Bethan
    Hughes, Daniel
    Sodi, Isabella
    Foster, Kane
    Lyon, Emma
    Laidler, Annabel
    Rees, Elise
    Galas-Filipowicz, Daria
    Fitzsimons, Evie
    Chavda, Selina
    Rashid, Ambreen
    Lecat, Catherine
    Mehta, Dipal
    Rahman, Jasmin
    Yoon, Jong Won
    Lee, Lydia
    Quezada, Sergio
    Srinivasan, Anandagopal
    Kazeroun, Mohammad
    Ansari-Pour, Naser
    Thakurta, Anjan
    Yong, Kwee
    Cribbs, Adam
    Gooding, Sarah
    Boyle, Eileen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S163 - S164
  • [35] Real world efficacy and safety of venetoclax in t(11;14) multiple myeloma in Hungary
    Szita, Virag
    Mikala, Gabor
    Kozma, Andras
    Fabian, Janos
    Hardi, Apor
    Alizadeh, Hussain
    Rajnics, Peter
    Varoczy, Laszlo
    Rejto, Laszlo
    Szendrei, Tamas
    Illes, Arpad
    Valyi-Nagy, Istvan
    Masszi, Tamas
    Varga, Gergely
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S86 - S87
  • [36] Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba, Merav
    Duek, Adrian
    Amariglio, Ninette
    Avigdor, Abraham
    Benyamini, Noam
    Hardan, Izhar
    Zilbershats, Itay
    Ganzel, Chezi
    Shevetz, Olga
    Novikov, Ilya
    Cohen, Yossi
    Ishoev, Galina
    Rozic, Gabriela
    Nagler, Arnon
    Trakhtenbrot, Luba
    GENES CHROMOSOMES & CANCER, 2016, 55 (09) : 710 - 718
  • [37] Liquid biopsy for t(11;14)/blc2 identification in multiple myeloma
    Spencer, Andrew
    Mithraprabhu, Sridurga
    Shah, Jaynish
    Choi, Kawa
    George, Ashley
    Hader, Carlos
    Khong, Tiffany
    CANCER RESEARCH, 2022, 82 (12)
  • [38] Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
    Kumar, Shaji
    Kaufman, Jonathan L.
    Gasparetto, Cristina
    Mikhael, Joseph
    Vij, Ravi
    Pegourie, Brigitte
    Benboubker, Lofti
    Facon, Thierry
    Amiot, Martine
    Moreau, Philippe
    Punnoose, Elizabeth A.
    Alzate, Stefanie
    Dunbar, Martin
    Xu, Tu
    Agarwal, Suresh K.
    Enschede, Sari Heitner
    Leverson, Joel D.
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Touzeau, Cyrille
    BLOOD, 2017, 130 (22) : 2401 - 2409
  • [39] The incidence of translocation t(11;14) among patients with multiple myeloma in a single clinic
    Jew, Scott
    Goldwater, Marissa-Skye
    Bujarski, Sean
    Regidor, Bernard
    Emamy-Sadr, Marsiye
    Swift, Regina
    Eades, Benjamin
    Said, Jonathan
    Berenson, James R.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 161 (01) : 16 - 23
  • [40] Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials
    Avigan, Zachary M.
    Richter, Joshua
    ONCOLOGY-NEW YORK, 2024, 38 (06):
12345